4-[1-hydroxy-2-(N-dodecylsulfonamido)]ethyl-2-triethylsilylfuran | 139961-34-5

• 分子结构分类: 有机化合物 - 有机金属化合物 - 有机类金属化合物
• 英文名称: 4-[1-hydroxy-2-(N-dodecylsulfonamido)]ethyl-2-triethylsilylfuran
• 英文别名: 4-[1-hydroxy-2-(dodecansulfonylamido)ethyl]2-triethylsilylfuran；N-[2-hydroxy-2-(5-triethylsilylfuran-3-yl)ethyl]dodecane-1-sulfonamide
• CAS: 139961-34-5
• 化学式: C₂₄H₄₇NO₄SSi
• 分子量: 473.793
• InChiKey: DOJCUQPNPIONGE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.87
• 重原子数：
  31
• 可旋转键数：
  19
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  87.9
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4-[1-hydroxy-2-(N-dodecylsulfonamido)]ethyl-2-triethylsilylfuran 在 吡啶 、 乙酸酐 作用下， 以 正己烷 、 乙酸乙酯 为溶剂， 生成 4-[1-acetoxy-2-(N-dodecylsulfonamido)]ethyl-2-triethylsilylfuran
  参考文献：
  名称：

  4-(1-hydroxy-2-N-substituted sulfonamido)

  摘要：

  化合物的化学式1和化学式2如下所示：其中R.sub.1为H或含有1至20个碳原子的烷基，CO--R.sub.1.sup.*，CO--O--R.sub.1.sup.*，CO--NH--R.sub.1.sup.*或PO(OR.sub.1.sup.*).sub.2或PO(OR.sub.1.sup.*)R.sub.1.sup.*，其中R.sub.1.sup.*独立地为H，含有1至20个碳原子的烷基，苯基或取代苯基；R.sub.2为H，含有1至20个碳原子的烷基，或R.sub.2和Y共同代表一个杂环，其中该杂环将磺胺酰胺氮原子作为杂原子；R.sub.3为H或含有1至20个碳原子的烷基；X为H，R.sub.4，CO--R.sub.4，CO--O--R.sub.4，CO--NH--R.sub.4，CO--N--(R.sub.4).sub.2，PO(OR.sub.4).sub.2或PO(OR.sub.4)R.sub.4，其中R.sub.4独立地为H，苯基，取代苯基，含有1至20个碳原子的烷基或含有1至20个碳原子的烷基，其被羟基，烷氧基，取代氨基，硫代烷氧基，O--COR.sub.4.sup.*基或COR.sub.4.sup.*基取代，其中R.sub.4.sup.*为H，低碳烷基，OH，OR.sub.4.sup**，NH.sub.2，NHR.sub.4.sup**或N(R.sub.4.sup**).sub.2基，其中R.sub.4.sup.**独立地为H或低碳烷基，但当X为CO--O--R.sub.4或CO--NH--R.sub.4时，R.sub.4不为氢，Y为H，苯基或取代苯基，含有1至20个碳原子的烷基，或含有1至20个碳原子的烷基，其被羟基，烷氧基，取代氨基，硫代烷氧基，O--PO(OR.sub.5).sub.2，O--PO(OR.sub.5)R.sub.5，O--SO.sub.3 H，O--SO.sub.2 R.sub.5，O--COR.sub.5或COR.sub.5基取代，其中R.sub.5为H，低碳烷基，OH，OR.sub.5.sup*，NH.sub.2，NHR.sub.5.sup*或N(R.sub.5.sup*).sub.2基，其中R.sub.5.sup*为低碳烷基，或R.sub.2和Y共同代表一个杂环，其中该杂环将磺胺酰胺氮原子作为杂原子，但当Y为含有O--PO(OR.sub.5).sub.2或O--PO(OR.sub.5)R.sub.5取代的烷基时，R.sub.5不为OH。这些化合物具有抗炎活性。

  公开号：

  US05081261A1

文献信息

• Intermediates and processes for preparing 4-substituted 2-5(H)-furanones
  申请人：Allergan, Inc.

  公开号：US05082954A1

  公开（公告）日：1992-01-21

  Anti-inflammatory 4-substituted 2-furanones are made from intermediates having the formulas: ##STR1## in which R.sub.1, R.sub.2 and R.sub.3 independently are n-alkyl of 1 to 6 carbons, or branched chain alkyl of 1 to 6 carbons; X is H, OH, NH.sub.2, I or Br; R.sub.4 is H, alkyl of 1-20 carbons, phenyl[C.sub.1 -C.sub.20 alkyl], naphthyl[C.sub.1 -C.sub.20 alkyl], CH.sub.2 OH, CH.sub.2 NH.sub.2, CH.sub.2 CH.sub.2 OH, CH.sub.2 --CHO, CH.sub.2 --COOH or CH.sub.2 --COOR.sub.5, and R.sub.5 is alkyl of 1 to 6 carbons, with the proviso that when X is hydrogen then R.sub.4 is selected from the group consisting of CH.sub.2 OH, CH.sub.2 NH.sub.2, CH.sub.2 CH.sub.2 OH, CH.sub.2 --CHO, or CH.sub.2 --COOR.sub.5 ; ##STR2## in which R.sub.1, R.sub.2 and R.sub.3 independently are n-alkyl of 1 to 6 carbons, or branched chain alkyl or 1 to 6 carbons, and R.sub.5 is alkyl or 1 to 6 carbons; ##STR3## in which R.sub.1, R.sub.2 and R.sub.3 independently are n-alkyl of 1 to 6 carbons, or branched chain alkyl of 1 to 6 carbons, and R.sub.6 is phenyl, or alkyl of 1 to 6 carbons, and ##STR4## in which R.sub.1, R.sub.2 and R.sub.3 independently are n-alkyl of 1 to 6 carbons, or branched chain alkyl of 1 to 6 carbons.

  抗炎症的4-取代的2-呋喃酮是由具有以下结构的中间体制备的：##STR1## 其中R.sub.1，R.sub.2和R.sub.3独立地是1到6个碳原子的n-烷基，或者1到6个碳原子的支链烷基；X是H，OH，NH.sub.2，I或Br；R.sub.4是H，1-20个碳原子的烷基，苯基[C.sub.1-C.sub.20烷基]，萘基[C.sub.1-C.sub.20烷基]，CH.sub.2 OH，CH.sub.2 NH.sub.2，CH.sub.2 CH.sub.2 OH，CH.sub.2 --CHO，CH.sub.2 --COOH或CH.sub.2 --COOR.sub.5，而R.sub.5是1到6个碳原子的烷基，但当X为氢时，R.sub.4从CH.sub.2 OH，CH.sub.2 NH.sub.2，CH.sub.2 CH.sub.2 OH，CH.sub.2 --CHO或CH.sub.2 --COOR.sub.5的组中选择；##STR2## 其中R.sub.1，R.sub.2和R.sub.3独立地是1到6个碳原子的n-烷基，或者1到6个碳原子的支链烷基，而R.sub.5是1到6个碳原子的烷基；##STR3## 其中R.sub.1，R.sub.2和R.sub.3独立地是1到6个碳原子的n-烷基，或者1到6个碳原子的支链烷基，而R.sub.6是苯基，或者1到6个碳原子的烷基，以及##STR4## 其中R.sub.1，R.sub.2和R.sub.3独立地是1到6个碳原子的n-烷基，或者1到6个碳原子的支链烷基。
• 4-(1-hydroxy-2-N-substituted sulfonamido)
  申请人：Allergan, Inc.

  公开号：US05081261A1

  公开（公告）日：1992-01-14

  Compounds of Formula 1, and of Formula 2, ##STR1## in which R.sub.1 is H or alkyl of 1 to 20 carbons, CO--R.sub.1.sup.* CO--O--R.sub.1.sup.* CO--NH--R.sub.1.sup.* or PO(OR.sub.1.sup.*).sub.2 or PO(OR.sub.1.sup.*)R.sub.1.sup.* where R.sub.1.sup.* independently is H, alkyl of 1 to 20 carbons, phenyl, or substituted phenyl; R.sub.2 is H, alkyl of 1 to 20 carbons, or R.sub.2 and Y jointly represent a heterocycle which incorporates the sulfonamide nitrogen in the ring as a heteroatom; R.sub.3 is H or alkyl of 1 to 20 carbons; X is H, R.sub.4, CO--R.sub.4, CO--O--R.sub.4, CO--NH--R.sub.4, CO--N--(R.sub.4).sub.2, PO(OR.sub.4).sub.2 or PO(OR.sub.4)R.sub.4, and R.sub.4 independently is H, phenyl, substituted phenyl, alkyl of 1 to 20 carbons or is alkyl of 1 to 20 carbons substituted with a hydroxyl, alkoxy, substituted amino, thioalkoxy, with a O--COR.sub.4.sup.* group or with a COR.sub.4.sup.* group where R.sub.4.sup.* is H, lower alkyl, OH, OR.sub.4.sup.**, NH.sub.2, NHR.sub.4.sup.** or N(R.sub.4.sup.**).sub.2 group where R.sub.4.sup.** independently is H or lower alkyl, with the proviso that when X is CO--O--R.sub.4 or is CO--NH--R.sub.4 then R.sub.4 is not hydrogen, and Y is H, phenyl or substituted phenyl, or alkyl of 1 to 20 carbons, or is alkyl of 1 to 20 carbons substituted with a hydroxyl, alkoxy, substituted amino, thioalkoxy, O--PO(OR.sub.5).sub.2, O--PO(OR.sub.5)R.sub.5, O--SO.sub.3 H, O--SO.sub.2 R.sub.5, O--COR.sub.5, or COR.sub.5 group where R.sub.5 is H, lower alkyl, OH, OR.sub.5.sup.*, NH.sub.2, NHR.sub.5.sup.* or N(R.sub.5.sup.*).sub.2 group where R.sub.5.sup.* is lower alkyl, or R.sub.2 and Y jointly represent a heterocycle which incorporates the sulfonamide nitrogen in the ring as a heteroatom, with the proviso that when Y is an alkyl substituted with O--PO(OR.sub.5).sub.2 or with O--PO(OR.sub. 5)R.sub.5 then R.sub.5 is not OH, are disclosed. The compounds possess anti-inflammatory activity.

  化合物的化学式1和化学式2如下所示：其中R.sub.1为H或含有1至20个碳原子的烷基，CO--R.sub.1.sup.*，CO--O--R.sub.1.sup.*，CO--NH--R.sub.1.sup.*或PO(OR.sub.1.sup.*).sub.2或PO(OR.sub.1.sup.*)R.sub.1.sup.*，其中R.sub.1.sup.*独立地为H，含有1至20个碳原子的烷基，苯基或取代苯基；R.sub.2为H，含有1至20个碳原子的烷基，或R.sub.2和Y共同代表一个杂环，其中该杂环将磺胺酰胺氮原子作为杂原子；R.sub.3为H或含有1至20个碳原子的烷基；X为H，R.sub.4，CO--R.sub.4，CO--O--R.sub.4，CO--NH--R.sub.4，CO--N--(R.sub.4).sub.2，PO(OR.sub.4).sub.2或PO(OR.sub.4)R.sub.4，其中R.sub.4独立地为H，苯基，取代苯基，含有1至20个碳原子的烷基或含有1至20个碳原子的烷基，其被羟基，烷氧基，取代氨基，硫代烷氧基，O--COR.sub.4.sup.*基或COR.sub.4.sup.*基取代，其中R.sub.4.sup.*为H，低碳烷基，OH，OR.sub.4.sup**，NH.sub.2，NHR.sub.4.sup**或N(R.sub.4.sup**).sub.2基，其中R.sub.4.sup.**独立地为H或低碳烷基，但当X为CO--O--R.sub.4或CO--NH--R.sub.4时，R.sub.4不为氢，Y为H，苯基或取代苯基，含有1至20个碳原子的烷基，或含有1至20个碳原子的烷基，其被羟基，烷氧基，取代氨基，硫代烷氧基，O--PO(OR.sub.5).sub.2，O--PO(OR.sub.5)R.sub.5，O--SO.sub.3 H，O--SO.sub.2 R.sub.5，O--COR.sub.5或COR.sub.5基取代，其中R.sub.5为H，低碳烷基，OH，OR.sub.5.sup*，NH.sub.2，NHR.sub.5.sup*或N(R.sub.5.sup*).sub.2基，其中R.sub.5.sup*为低碳烷基，或R.sub.2和Y共同代表一个杂环，其中该杂环将磺胺酰胺氮原子作为杂原子，但当Y为含有O--PO(OR.sub.5).sub.2或O--PO(OR.sub.5)R.sub.5取代的烷基时，R.sub.5不为OH。这些化合物具有抗炎活性。